FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890512945> ?p ?o ?g. }

• W2890512945 endingPage "897" @default.
• W2890512945 startingPage "880" @default.
• W2890512945 abstract "Background No regenerative approach has thus far been shown to be effective in skeletal muscle injuries, despite their high frequency and associated functional deficits. We sought to address surgical trauma-related muscle injuries using local intraoperative application of allogeneic placenta-derived, mesenchymal-like adherent cells (PLX-PAD), using hip arthroplasty as a standardized injury model, because of the high regenerative and immunomodulatory potency of this cell type. Methods Our pilot phase I/IIa study was prospective, randomized, double blind, and placebo-controlled. Twenty patients undergoing hip arthroplasty via a direct lateral approach received an injection of 3.0 × 108 (300 M, n = 6) or 1.5 × 108 (150 M, n = 7) PLX-PAD or a placebo (n = 7) into the injured gluteus medius muscles. Results We did not observe any relevant PLX-PAD-related adverse events at the 2-year follow-up. Improved gluteus medius strength was noted as early as Week 6 in the treatment-groups. Surprisingly, until Week 26, the low-dose group outperformed the high-dose group and reached significantly improved strength compared with placebo [150 M vs. placebo: P = 0.007 (baseline adjusted; 95% confidence interval 7.6, 43.9); preoperative baseline values mean ± SE: placebo: 24.4 ± 6.7 Nm, 150 M: 27.3 ± 5.6 Nm], mirrored by an increase in muscle volume [150 M vs. placebo: P = 0.004 (baseline adjusted; 95% confidence interval 6.0, 30.0); preoperative baseline values GM volume: placebo: 211.9 ± 15.3 cm3 , 150 M: 237.4 ± 27.2 cm3 ]. Histology indicated accelerated healing after cell therapy. Biomarker studies revealed that low-dose treatment reduced the surgery-related immunological stress reaction more than high-dose treatment (exemplarily: CD16+ NK cells: Day 1 P = 0.06 vs. placebo, P = 0.07 vs. 150 M; CD4+ T-cells: Day 1 P = 0.04 vs. placebo, P = 0.08 vs. 150 M). Signs of late-onset immune reactivity after high-dose treatment corresponded to reduced functional improvement. Conclusions Allogeneic PLX-PAD therapy improved strength and volume of injured skeletal muscle with a reasonable safety profile. Outcomes could be positively correlated with the modulation of early postoperative stress-related immunological reactions." @default.
• W2890512945 created "2018-09-27" @default.
• W2890512945 creator A5003226722 @default.
• W2890512945 creator A5003394793 @default.
• W2890512945 creator A5004124483 @default.
• W2890512945 creator A5009383130 @default.
• W2890512945 creator A5010748652 @default.
• W2890512945 creator A5014046098 @default.
• W2890512945 creator A5015114145 @default.
• W2890512945 creator A5025108864 @default.
• W2890512945 creator A5032358481 @default.
• W2890512945 creator A5038986793 @default.
• W2890512945 creator A5048731718 @default.
• W2890512945 creator A5049060150 @default.
• W2890512945 creator A5061694042 @default.
• W2890512945 creator A5067447491 @default.
• W2890512945 creator A5069236094 @default.
• W2890512945 creator A5069451422 @default.
• W2890512945 creator A5075445828 @default.
• W2890512945 creator A5084035322 @default.
• W2890512945 creator A5086141341 @default.
• W2890512945 date "2018-09-19" @default.
• W2890512945 modified "2023-10-13" @default.
• W2890512945 title "Immunomodulatory placental-expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty" @default.
• W2890512945 cites W1511347124 @default.
• W2890512945 cites W1520307927 @default.
• W2890512945 cites W1961872232 @default.
• W2890512945 cites W19695552 @default.
• W2890512945 cites W1979493465 @default.
• W2890512945 cites W1980285125 @default.
• W2890512945 cites W1987073290 @default.
• W2890512945 cites W1991096289 @default.
• W2890512945 cites W2007398635 @default.
• W2890512945 cites W2023627055 @default.
• W2890512945 cites W2025371271 @default.
• W2890512945 cites W2036376032 @default.
• W2890512945 cites W2050709987 @default.
• W2890512945 cites W2054964759 @default.
• W2890512945 cites W2063868046 @default.
• W2890512945 cites W2080238550 @default.
• W2890512945 cites W2086960980 @default.
• W2890512945 cites W2088883625 @default.
• W2890512945 cites W2093468534 @default.
• W2890512945 cites W2097946334 @default.
• W2890512945 cites W2100089205 @default.
• W2890512945 cites W2115740727 @default.
• W2890512945 cites W2118766051 @default.
• W2890512945 cites W2123522324 @default.
• W2890512945 cites W2132371677 @default.
• W2890512945 cites W2133405196 @default.
• W2890512945 cites W2134443544 @default.
• W2890512945 cites W2137241444 @default.
• W2890512945 cites W2146627681 @default.
• W2890512945 cites W2149993139 @default.
• W2890512945 cites W2159733957 @default.
• W2890512945 cites W2316395586 @default.
• W2890512945 cites W2324719142 @default.
• W2890512945 cites W2765244546 @default.
• W2890512945 cites W2767262401 @default.
• W2890512945 cites W4320301116 @default.
• W2890512945 cites W61571562 @default.
• W2890512945 doi "https://doi.org/10.1002/jcsm.12316" @default.
• W2890512945 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6204595" @default.
• W2890512945 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30230266" @default.
• W2890512945 hasPublicationYear "2018" @default.
• W2890512945 type Work @default.
• W2890512945 sameAs 2890512945 @default.
• W2890512945 citedByCount "45" @default.
• W2890512945 countsByYear W28905129452018 @default.
• W2890512945 countsByYear W28905129452019 @default.
• W2890512945 countsByYear W28905129452020 @default.
• W2890512945 countsByYear W28905129452021 @default.
• W2890512945 countsByYear W28905129452022 @default.
• W2890512945 countsByYear W28905129452023 @default.
• W2890512945 crossrefType "journal-article" @default.
• W2890512945 hasAuthorship W2890512945A5003226722 @default.
• W2890512945 hasAuthorship W2890512945A5003394793 @default.
• W2890512945 hasAuthorship W2890512945A5004124483 @default.
• W2890512945 hasAuthorship W2890512945A5009383130 @default.
• W2890512945 hasAuthorship W2890512945A5010748652 @default.
• W2890512945 hasAuthorship W2890512945A5014046098 @default.
• W2890512945 hasAuthorship W2890512945A5015114145 @default.
• W2890512945 hasAuthorship W2890512945A5025108864 @default.
• W2890512945 hasAuthorship W2890512945A5032358481 @default.
• W2890512945 hasAuthorship W2890512945A5038986793 @default.
• W2890512945 hasAuthorship W2890512945A5048731718 @default.
• W2890512945 hasAuthorship W2890512945A5049060150 @default.
• W2890512945 hasAuthorship W2890512945A5061694042 @default.
• W2890512945 hasAuthorship W2890512945A5067447491 @default.
• W2890512945 hasAuthorship W2890512945A5069236094 @default.
• W2890512945 hasAuthorship W2890512945A5069451422 @default.
• W2890512945 hasAuthorship W2890512945A5075445828 @default.
• W2890512945 hasAuthorship W2890512945A5084035322 @default.
• W2890512945 hasAuthorship W2890512945A5086141341 @default.
• W2890512945 hasBestOaLocation W28905129451 @default.
• W2890512945 hasConcept C141071460 @default.
• W2890512945 hasConcept C142724271 @default.
• W2890512945 hasConcept C16930146 @default.

• next